HOUSTON — Dr. Mei Rui, a concert pianist and Yale-trained molecular biochemist who directs Music-in-Medicine at MD Anderson Cancer Center, is working to transform how medicine evaluates and uses music in clinical care. Her effort centers on replacing imprecise descriptions such as "relaxing music" or "classical music" with reproducible, measurable musical parameters tied to biological outcomes.
Why the sound matters
For decades, studies of music-based interventions have too often treated the music itself as a background detail, according to Rui and co-authors in a 2026 review published in eClinicalMedicine. That omission, she says, obscures the role of compositional and acoustic features that may shape neural networks, autonomic responses and cardiovascular activity.
"without precise and reproducible characterization of compositional elements and acoustic parameters."
Those unstated features include elements that musicians consider fundamental: timbre, phrasing, harmonic structure, rubato, articulation, tempo, dynamic range and the piece's emotional trajectory. Rui argues that two trials labeled as testing the same musical intervention can actually expose patients to markedly different stimuli, weakening reproducibility and hindering clinical translation.
From concert stage to clinical trials
Rui’s dual career — as an internationally performing pianist and an academic scientist and neurosurgery faculty member — is the methodological foundation for her approach. She combines a musician’s ear for nuance with laboratory and clinical tools to design trials driven by measurable biomarkers rather than generic genre labels. At MD Anderson she is developing protocols that specify musical content and relate acoustic parameters to physiological and molecular outcomes.
The implications are practical. Poorly defined interventions complicate comparisons across studies and slow progress toward evidence-based recommendations. If music is to be prescribed in clinical settings, clinicians and regulators will require consistency and reproducibility comparable to that expected for pharmacologic or device interventions.
Steps toward standardization
Rui and colleagues advocate for a rigorous taxonomy of musical elements and the use of acoustic analytics to quantify interventions. Such work would allow researchers to:
- Specify measurable acoustic parameters for each intervention
- Link defined musical features to physiological and molecular biomarkers
- Improve comparability and reproducibility across trials
Those steps reflect an effort to move music medicine from varied, often anecdotal practice into standardized clinical research and, ultimately, clinical care.
| Problem | Proposed response |
|---|---|
| Vague intervention descriptions | Define acoustic and compositional parameters |
| Low reproducibility across trials | Use quantified musical metrics and biomarkers |
Broader consequences
Standardizing musical interventions could speed clinical translation and enable regulatory evaluation, but it also raises questions about how to operationalize art within medical evidence frameworks. Rui’s work sits at that intersection, leveraging musical expertise to address methodological shortcomings that statisticians and clinicians may not detect without such domain knowledge.
As music-based therapies gain attention for symptom relief, stress reduction and potential modulation of physiological systems, the field faces a choice: continue with loosely described, variable interventions or adopt the kind of precision Rui calls for. Her research agenda — emphasizing reproducible musical descriptions paired with biomarker endpoints — aims to make music a credible, measurable adjunct in clinical practice.
Whether that will lead to routine prescriptions of specific pieces or performances remains to be determined, but the effort reframes music medicine as a discipline that must meet the same standards of definition and measurement required of other therapeutic modalities.
